Natixis Advisors LLC Buys 7,564 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Natixis Advisors LLC grew its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 38.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,158 shares of the biopharmaceutical company’s stock after purchasing an additional 7,564 shares during the quarter. Natixis Advisors LLC’s holdings in Xenon Pharmaceuticals were worth $1,069,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. GSA Capital Partners LLP boosted its holdings in Xenon Pharmaceuticals by 475.9% during the third quarter. GSA Capital Partners LLP now owns 37,308 shares of the biopharmaceutical company’s stock valued at $1,469,000 after acquiring an additional 30,830 shares during the period. TimesSquare Capital Management LLC lifted its position in shares of Xenon Pharmaceuticals by 3.2% during the 3rd quarter. TimesSquare Capital Management LLC now owns 778,293 shares of the biopharmaceutical company’s stock worth $30,641,000 after purchasing an additional 23,800 shares during the last quarter. Assetmark Inc. lifted its position in shares of Xenon Pharmaceuticals by 7.9% during the 3rd quarter. Assetmark Inc. now owns 19,670 shares of the biopharmaceutical company’s stock worth $774,000 after purchasing an additional 1,435 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Xenon Pharmaceuticals by 99.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 48,063 shares of the biopharmaceutical company’s stock valued at $1,892,000 after purchasing an additional 23,947 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Xenon Pharmaceuticals by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,572 shares of the biopharmaceutical company’s stock valued at $574,000 after buying an additional 5,704 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Stock Up 1.8 %

Shares of XENE stock opened at $42.45 on Wednesday. The firm has a market capitalization of $3.24 billion, a price-to-earnings ratio of -15.05 and a beta of 1.25. Xenon Pharmaceuticals Inc. has a 12-month low of $29.00 and a 12-month high of $50.99. The firm has a fifty day moving average of $41.31 and a 200-day moving average of $40.20.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the business posted ($0.73) earnings per share. Research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Raymond James reissued an “outperform” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Needham & Company LLC restated a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. William Blair raised Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $57.45.

Insider Buying and Selling

In other news, Director Gary Patou sold 4,891 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total transaction of $200,922.28. Following the sale, the director now owns 23,573 shares in the company, valued at $968,378.84. This represents a 17.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 5.52% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.